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Background: Phosphoribosyl pyrophosphate synthetase (PRS) I deficiency is a rare medical condition caused by
missense mutations in PRPS1 that lead to three different phenotypes: Arts Syndrome (MIM 301835), X-linked
Charcot-Marie-Tooth (CMTX5, MIM 311070) or X-linked non-syndromic sensorineural deafness (DFN2, MIM 304500).
All three are X-linked recessively inherited and males affected display variable degree of central and peripheral
neuropathy. We applied whole exome sequencing to a three-generation family with optic atrophy followed by
retinitis pigmentosa (RP) in all three cases, and ataxia, progressive peripheral neuropathy and hearing loss with
variable presentation.
Methods: Whole exome sequencing was performed in two affecteds and one unaffected member of the family.
Sanger sequencing was used to validate and segregate the 12 candidate mutations in the family and to confirm
the absence of the novel variant in PRPS1 in 191 controls. The pathogenic role of the novel mutation in PRPS1
was assessed in silico and confirmed by enzymatic determination of PRS activity, mRNA expression and
sequencing, and X-chromosome inactivation.
Results: A novel missense mutation was identified in PRPS1 in the affected females. Age of onset, presentation
and severity of the phenotype are highly variable in the family: both the proband and her mother have
neurological and ophthalmological symptoms, whereas the phenotype of the affected sister is milder and
currently confined to the eye. Moreover, only the proband displayed a complete lack of expression of the wild
type allele in leukocytes that seems to correlate with the degree of PRS deficiency and the severity of the
phenotype. Interestingly, optic atrophy and RP are the only common manifestations to all three females and the
only phenotype correlating with the degree of enzyme deficiency.
Conclusions: These results are in line with recent evidence of the existence of intermediate phenotypes in PRS-I
deficiency syndromes and demonstrate that females can exhibit a disease phenotype as severe and complex as their
male counterparts.
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Phosphoribosyl pyrophosphate synthetase 1 (PRS-I, [MIM
311850]) is an ubiquitous enzyme with an essential role in
nucleotide metabolism: it catalyzes the synthesis of phos-
phoribosyl pyrophosphate (PRPP), the substrate for the
synthesis of purine, pyridine, and pyrimidine nucleotides
[1]. PRS-I has two highly homologous isoforms, PRS-II
(MIM 311860) widely expressed as PRS-I, and PRS-III
(MIM 611566) whose expression is restricted to testes.
The three isoforms are products of separate but highly
conserved genes: PRPS1 (Xq22.3), PRPS2 (Xp22.2), and
PRPS1L1 (7p21.1), respectively [2]. Missense mutations in
PRPS1 are rare and may result in increase or decrease in
PRS-I activity. PRS-I deficiency is an extremely rare con-
dition that can lead to three different disorders: Arts syn-
drome (MIM 301835), being the most extreme form of
enzyme deficiency; Rosenberg-Chutorian syndrome or
X-linked Charcot-Marie Tooth 5 (CMTX5, MIM 311070),
which represents a less severe phenotype; and X-linked
non-syndromic sensorineural deafness (DFN2, MIM
304500), as the mildest form of deficiency. Only twelve
families have been described so far with PRS-I deficiency
syndromes [3-7] [I. del Castillo, personal communication].
Hearing loss is the only common feature between the
three disorders and the only symptom observed in DFN2.
Arts syndrome and CMTX5 share additional neurological
anomalies such as ataxia, hypotonia, and optic atrophy
[4,8,9]. Arts syndrome is also characterized by delayed
motor development, mild to moderate intellectual disabil-
ity and frequent recurrent infections that typically result
in early death [3,10]. PRS-I superactivity (MIM 300661) is
more frequent than the deficiency and is characterized by
hyperuricemia and gout and it can be accompanied by
other neurological symptoms such as sensorineural deaf-
ness, hypotonia, mental retardation, and also by recurrent
infections [11,12]. All four disorders are inherited in a
recessive X-linked manner so only males are affected.
Obligate female carriers, however, may occasionally dis-
play milder symptoms such as hearing loss in CMTX5
[8,9], hearing impairment, ataxia, hypotonia or hyperre-
flexia in Arts syndrome [3], or hyperuricemia in PRS-I
superactivity [13].
Using whole exome sequencing (WES), we identified a
novel loss-of-function mutation in PRPS1 leading to en-
zyme deficiency in three females with optic atrophy (OA),
retinitis pigmentosa (RP), ataxia, peripheral neuropathy
and hearing loss with variable presentation.
Methods
Subjects
A three-generation Spanish family (RP-0482) consisting of
four affected females (Figure 1A) was recruited and evalu-
ated by the Fundacion Jimenez Diaz Hospital (Madrid,
Spain). The four affecteds, six unaffecteds and two unrelatedmembers of the family participated in the genetic study. All
four affected females, II:2, III:2, IV:2 and IV:3, displayed typ-
ical or sectorial RP and various degrees of neurological
symptoms. II: 2 and II:3 died during the course of the study
but we obtained their DNA samples and informed consent
before allowing us to include them in the study. Addition-
ally, 191 unrelated Spanish individuals with no history of ret-
inal dystrophy and randomly selected from blood donors
voluntarily participated as controls. Informed consent was
obtained from all individuals involved, all procedures were
reviewed and approved by the Ethics Committee of the
Hospital and adhered to the tenets of the Declaration
of Helsinki.
Whole exome sequencing and variant analysis
Genomic DNA was captured by Agilent SureSelect Human
All Exon kit version 2 covering 46 MB of coding region
(Agilent Technologies, Santa Clara, CA, USA), and se-
quenced on HiSeq 2000 instruments (Illumina, San Diego,
CA, USA). Raw reads were mapped to the human refer-
ence genome (UCSC hg19), using the Burrows–Wheeler
alignment tool [15]. Genome Analysis Tool Kit version 1.4
[16] was used for variant calling. ANNOVAR [17] was used
for variant functional annotation and prediction and con-
servation scores from SIFT [18], Polyphen2 [19], LRT [20],
MutationTaster [21], PhyloP [22] and GERP++ [23] were
retrieved from the Database for Nonsynonymous SNPs’
Functional Predictions [24] for every potential nonsynon-
ymous single nucleotide variant (SNVs).
Variant filtering was performed under the assumption of
dominant inheritance. Only nonsynonymous, splice site
disrupting, and frameshift heterozygous variants segregat-
ing in the family with a minor allele frequency ≤0.5% in a
control cohort of more than 8000 individuals (1000
Genomes Project, [25] (April, 2012 release); 6503 exomes
from NHLBI GO Exome Sequencing Project [26], and 669
in-house whole-exomes) were considered. Further gene
prioritization was performed combining data on minor al-
lele frequency, sequence conservation, potential deleteri-
ous effect and biological and clinical relevance according
to gene function, gene expression, and the existence of
mutation reports in databases such as The Human Gene
Mutation Database [27], The Retinal Information Network
(RetNet) [28] or Online Mendelian Inheritance in Man
(OMIM) [29].
Sanger sequencing
Sanger sequencing was used for the segregation of all
variants resulting from the filtering analysis in family
RP-0482 and to confirm the absence of variant p.Ser16-
Pro in PRPS1 in 191 Spanish controls (primers available
in Additional file 1). PCR products were enzymatically
purified with ExoSAP-it (USB, Affymetrix), sequenced on
both strands using Big Dye Terminator Cycle Sequencing
Figure 1 PSPS1 is mutated in females with syndromic retinitis pigmentosa from a three-generation family. A. Pedigree of family RP-0482
and validation by Sanger sequencing of p.Ser16Pro demonstrating the correct segregation in the family. All affected individuals (II:2, III:2; IV:2 and
IV:3) are heterozygous for the variant. Red circles indicate the individuals analysed by WES. Although II:2 and II:3 died during the course of the
study, DNA samples and informed consents were obtained before deceasing, allowing us to include those subjects in the segregation analysis.
B. Multiple sequence alignment of PRPS1 across species using ClustalW [14] confirms that p.Ser16 is identical from human to zebrafish. C. Schematic
representation of PRPS1 with the location of the novel heterozygous mutation p.Ser16Pro in exon 1 (in red) and previously known mutations in Arts
syndrome (in orange), PRS-I Superactivity (in green), Charcot-Marie-Tooth disease-5 (in blue), X-linked nonsyndromic sensorineural deafness (in purple),
and also the recently reported mutation associated with retinal dystrophy (in brown). Exons are indicated by rectangles that are wider for the coding
regions. Nucleotide numbering reflects cDNA in the reference sequence NM_002764. D. Model of PRS-I with p.Ser16Pro based on the crystal structure
of human PRS-I (PDB: 2H06) and close-up of the mutation showing the loss of a hydrogen bound with residue Gln13. E. RT-PCR and sequencing
analysis of p.Ser16Pro in mRNA. RNA was derived from peripheral blood lymphocytes of the three patients (IV:2, IV:3 and III:2) and an unaffected
control (IV:1). Normally spliced amplicons of exons 1–2, 1–4 and 4–7 of PRPS1 comprising 229, 559 and 564 nucleotides, respectively, were found in all
cases. Amplification of GAPDH mRNA analysis was used as positive control. Sanger sequencing of RT-PCR products evidences the absence of the
wild-type allele in the cDNA of the proband (IV:3).
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mated sequencer (ABI 3130xl Genetic Analyzer, Applied
Biosystems).
In silico analyses of p.Ser16Pro pathogenicity
The evolutionary conservation of p.Ser16Pro was assessed
by multiple sequence alignment of PRPS1 across species
using ClustalW2 [14]. The impact of the mutation in the
tridimensional structure of the protein was assessed with
a model of PRS-I with p.Ser16Pro based on the crystal
structure of the human protein (PDB: 2H06) using Swiss
Model [30,31] and Swiss PDB viewer [32]. ESEFinder[33,34] was used to determine whether p.Ser16Pro could
alter the normal splicing of the mRNA.
Determination of PRS activity in erythrocytes
PRS enzymatic activity was determined in erythrocytes
from III:2, III:3, IV:1, IV:2, and IV:3, according to the
method previously described by Torres et al. [35]. Interval
used as reference was 70–126 nmol/h/mg hemoglobin.
PRPS1 expression analysis
PRPS1 expression analysis was performed in RNA sam-
ples using blood lymphocytes from III:2, IV:1, IV:2, and
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ImProm-II™ Reverse Transcription System (Promega)
using random primers. RT-PCR experiments were per-
formed using PRPS1 exonic primers pairs spanning exons
1–2, 1–4, and 4–7 (primers available in the Additional file
1). Primers for the housekeeping GAPDH gene were used
as internal control. PCR fragments were subjected to elec-
trophoresis in a gel searching for abnormally spliced
amplicons and further sequenced.
X-chromosome inactivation
X chromosome inactivation assay was performed in so-
dium bisulfite-treated genomic DNA from peripheral
blood and saliva (EpiTect Bisulfite Kit, Quiagen) by a
methylation specific PCR of the first exon of the human
androgen receptor locus with fluorochrome-coupled
primers. Heterozygosity of the human androgen receptor
region in the target samples was previously checked. Two
different pairs of primers were used to detect the methyl-
ated and unmethylated alleles and PCR fragments were an-
alyzed in an ABI PRISM 3100 Genetic Analyzer (Applied
Biosystems). X chromosome inactivation skewing was re-
ported as percentage of the predominant allele and was
considered skewed when the predominant allele exceeded
74%, non-skewed between 50% and 65% and undetermined
between 66% and 74% [36].
Results
Familial history of RP-0482
Data from ophthalmological, neurological and otological
examinations of patients III:2, IV:2, and IV:3 were
available from a period of more than 15 years and the
phenotype is described in detail in the Additional file 1.
Patient II:2 also displayed sectorial RP and ataxic
traits, but the progression of the clinical phenotype is
not available. Figure 2 shows the retinal and MRI im-
ages of the three affected females. Age of onset, pres-
entation and severity of the phenotype are highly
variable in the family, as summarized in Table 1. Both
the index patient and her mother have various de-
grees of ataxia, peripheral neuropathy and hearing
loss beyond the ophthalmological symptoms, whereas
the phenotype of the affected sister is currently con-
fined to the eye and milder than those of III:2 and
IV:3 (Additional files 1 and 2)
Identification of a novel missense mutation in PRSP1 by WES
DNA samples from individuals III:3, IV:2, and IV:3 were
subjected to WES (Figure 1A). A total of 10.77 GB data
on target genomic regions was generated for the three
samples, with a mean coverage of target region of 78.23X.
An average of 48,306 SNVs and 8,218 insertion/deletion
(indels) were called for the three exomes, but for further
filtering only coding variants were considered, thusreducing the number to an average of 18,722 SNVs
and 741 indels per sample. Variant filtering under the
assumption of a dominant inheritance yielded 141 vari-
ants in 126 genes as potential candidates (Additional
file 3) with no known cause of retinal degeneration
amongst them (RetNet, [28] accessed June, 2013). Fur-
ther filtering of the 141 variants, left 12 novel variants,
conserved across species according to the values from
PhyloP and GERP++, predicted to be pathogenic at
least by two of the systems evaluated and with expres-
sion in the retina, so they were selected for validation
and segregation in the family (Additional file 1). Only
the novel missense change in exon 1 of PRPS1, c.46 T > C;
p.Ser16Pro (NM_001204402), completely segregated in all
four affecteds and eight unaffected members of family
RP-0482 (Figure 1A) and was absent in controls (258 X
chromosomes total). Both GERP++ and PhyloP values
estimated a high degree of conservation of serine at
position 16 of PRS-I across species (Additional file 3),
and was confirmed by multiple sequence alignment
(Figure 1B), being the first missense mutation identi-
fied in this gene from the first α-helix to the fourth
β-strand (aminoacids 1 to 43, Figure 1C). All in silico
programs evaluated except for Polyphen2 predicted p.
Ser16Pro to be damaging (Additional file 3). The tri-
dimesional model of PRS-I with p.Ser16Pro indicated
that Ser16 is located in the first α-helix of the protein
in the N-terminal domain (Figure 1D). The replace-
ment of serine with proline leads to the loss of a
hydrogen bond with Gln13 likely breaking the tightly
packed α-helix.p.Ser16Pro leads to PRS deficiency in females
To further assess the functional effect of the mutation
in vitro, PRS enzymatic activity was determined in eryth-
rocytes from three affected females (III:2, IV:2, and IV:3),
where different levels of enzyme deficiency were evi-
denced (Table 1), and two unaffecteds (III:3 and IV:1) with
PRS-I within the normal range.Lack of expression of PRPS1 p.Ser16 in the index patient
The in silico analysis using ESEFinder predicted this
mutation to alter the recognition pattern of splicing
RNA proteins compared to the wild type sequence. To
confirm this, PRPS1 expression analysis was performed
in RNA samples from blood lymphocytes from three
affecteds and one unaffected (IV:1). RT-PCR analysis
yielded no differences on the expression of PRPS1 tran-
scripts between carriers of p.Ser16Pro and the non-carrier
(Figure 1E), and no additional splicing transcripts were
found. Notably, further sequencing of mRNA transcripts
evidenced the mutation in homozygosis in the index
patient (Figure 1E).
Figure 2 Retinal and head MRI imaging of patients carrying the p.Ser16Pro variant in PRPS1. A-E. Retinal imaging of both eyes (BE) of the
proband IV:3 at age 35. (A-B) Fundus photographies show pale and atrophic papilla, narrowed vessels, diffuse hypopigmentation, bone spicules,
and retinal pigment epithelium (RPE) atrophy in the mid-periphery of BE, and a well-defined atrophic macular lesion in the right eye (RE).
(C) Autofluorescence reveals hypofluorescence areas corresponding with pigmented spicules and atrophic lesions. (D) Optical coherence
tomography (OCT) confirms the generalized atrophy in all retinal layers in both perifoveal and foveal regions in RE. Well-conserved retinal
architecture was found in the left eye (LE) and the atrophy is restricted to RPE and external layers. (E) Head MRI scan of the proband IV:3
demonstrates a moderate cerebellar atrophy (white arrows). F-J. Retinal imaging of BE of IV:2 at age 37. (F-G) Fundus photographies show a slight pallor in
the papilla, slight arteriolar attenuation mainly around the optic nerve, a normal macula and an incipient RPE atrophy. (H) Normal autofluorescence. (I) OCTs
display atrophy of photoreceptors layer in the perifoveal region and normal foveal thickness. (J) Head MRI scan of individual IV:2 does not evidence any sign of
cerebellar atrophy. K-O. Retinal imaging of BE of III:2 at age 70. (K-L) Fundus photographies evidence pale and atrophic papilla, substantially narrowed vessels,
sparse pigmentation, patches of chorioretinal atrophy in the mid-periphery of BE, and a well-defined atrophic macular lesion in RE and RPE alteration
in LE. (M) Autofluorescence imaging shows alternating areas of hypo and hyperfluorescence. (N) OCT shows subfoveal atrophy lesion with
loss of retinal architecture, an epiretinal membrane in RE and defects in external layer in LE. (O) Head MRI scan of individual III:2 exhibits a
mild cerebellar atrophy (white arrow).
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the index patient
Non-random patterns of X-chromosome inactivation were
assessed in the three affecteds (III:2, IV:2 and IV:3) and
one unaffected individual (IV:1). Only in IV:3, there was a
significantly skewed inactivation (82%) of the paternal
allele, which explains the lack of expression of the
wild type allele observed in the mRNA (Figure 1E).
Individuals IV:1, IV:2 and III:2, had 50%, 61% and
64% X-chromosome inactivation, respectively, so they
were considered non-skewed.Discussion
Here we report a novel mutation in PRPS1 leading to
PRS-I deficiency in three-females from a family with a
phenotype consisting of OA followed by RP in all cases,
plus neurological features overlapping CMTX5 and Arts
syndrome with variable presentation in the proband
(IV:3) and her mother (III:2).
Despite being already described that carrier females of
PRPS1 mutations can exhibit PRS-I deficiency and a dis-
ease phenotype [3,7-9], to date, no female has been re-
ported to display such a complex and severe phenotype
Table 1 Summary of findings in family RP-0482 and comparison with other PRS-I deficiency disorders (adapted from
de Brouwer et al. [11])
IV:3 IV:2 III:2 Arts syndrome CMTX5 DFN2
Date of birth 1978 1976 1943
Symptoms (age at diagnosis)
Ophthalmological
Retinitis Pigmentosa + (14y) + (23y) + (47y) - - -
Night blindness ++ (4y) + (16y) + - - -
Visual field constriction ++ + + - - -
Visual acuity loss ++ (4y) - ++ - - -
ERG alteration ++ +/− ++ - - -
Pigmentary changes at fundus + +/− + - - -
Macular atrophy ++ + + - - -
Optic atrophy + (5y) + (16y) + (47y) + + (~10y) +
Nystagmus + (Congenital) - - - - -
Cataracts + - + - - -
Hyperopia + + +/− - - -
Hearing impairment ++ (21y) - + (50y) ++ + +
Neurological ++ (34y) - + (55y)
Mild developement delay +/− - - + - -
Hypotonia + - - + + -
Delayed motor development - - - + - -
Peripheral neuropathy ++ - + + + -
Pes cavus + - - NR NR NR
Loss of deep tendom reflexes - - - - + -
Cerebellar Atrophy ++ - +
Ataxia + - + + + -
Essential tremor + + +














Structural effect of mutation Whole protein structure? ATP site and allosteric




The number of “+” indicate the severity of the manifestation. NR = Not reported and EBV-LCLs = Epstein-Barr virus–transformed lymphoblastoid cell lines.
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patient showed a phenotype with features of Arts syn-
drome and CMTX5, with optic atrophy as the first
symptom, followed by RP and neurological manifesta-
tions, such as hearing loss, intellectual disability and per-
ipheral neuropathy (Table 1). The findings from this
patient are consistent with the increasing evidence of
intermediate phenotypes in PRS-I syndromes, recently
described by several authors [6,7,12,37]. In particular,
Synofzik and colleagues recently described a male with
an intermediate phenotype between CMTX5 and Artssyndrome and a carrier female affected with DFN2 due
to X-chromosome inactivation skewing [7]. The authors
observed a correlation between the enzymatic residual
activity, the degree of X chromosome inactivation skew-
ing and the phenotype in the female and postulated that
the location of the mutation and the residual enzymatic
activity would be the main determinants of the pheno-
typic manifestations in males and females, respectively
[7]. The three affected females from our family exhibited
different levels of PRS deficiency in erythrocytes, ranging
from a severe decrease in the activity in IV:3 to an
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patterns of X-chromosome inactivation were exclusively
observed for the index patient (IV:3), who was found to
only express the mutant allele in lymphocytes. In this
patient, there was an apparent correlation between the
X-chromosome inactivation in leukocytes, the lack of ex-
pression of the wild type allele in lymphocytes, the de-
gree of PRS deficiency in erythrocytes, and the severity
of the phenotype. X chromosome inactivation in subjects
III:2 and IV:2 was not skewed and the degree of PRS-I
deficiency only correlated with the age of onset of oph-
thalmological symptoms but not with the presentation
or severity of the phenotype. This lack of correlation is
not surprising given that X-inactivation, whether ran-
dom or biased, occurs in a tissue-specific manner and
what is observed in a particular tissue or cell type, such
as leukocytes may not be representative of the status of
central and peripheral nervous systems [7,38], which are
primarily affected in PRS-I deficiency syndromes. Given
the variable expression of the disease in the family it is
very possible that either X-inactivation is skewed in
those target systems or that the expression of PRS-II is
compensating PRS enzymatic function as previously sug-
gested, and so phosphoribosyl pyrophosphate synthesis
would not be critically affected [11].
A relationship between the level of PRS-I disruption
and the different syndromic manifestations has been
suggested [11], with the most severe syndromes caused
by mutations predicted to impact allosteric and active
sites and those responsible for milder phenotypes dis-
rupting the structure locally [11]. Very recently, Al-
Maawali and colleagues expanded the PRPS1 phenotype
to retinal dystrophy and diabetes insipidus in a family
with two males affected with Leber’s congenital amaur-
osis along with other manifestations, and no carrier female
affected [37]. The mutation responsible for the phenotype
was located in exon 5 of the gene (p.Arg196Trp), close to
the ATP binding site of PRS-I. Residue Ser16 is located in
the N-terminal domain of the protein, in a region not pre-
viously found mutated (Figure 1C) and far from the allo-
steric and active sites, both associated with Arts syndrome,
CMTX5, and the recent retinal dystrophy phenotype, all
features harbored by this family. That demonstrates once
again the mutation-specific nature of PRS-I phenotypes
[7,11]. Nevertheless, the existence of a putative defective
splicing isoform, as predicted by in silico analysis cannot be
ruled out, as it would be degraded by nonsense-mediated
decay and thus, would not be detected by RT-PCR. In
addition, other genes or epigenomic factors could be con-
tributing to the complexity and severity of the phenotypes
of PRS-I syndromes. Finally, it is worth noting that we can-
not rule out either a dominant inheritance pattern for this
particular mutation with a lethal effect in hemizygotes due
to the lack of affected males in the family.Conclusion
These results support previous findings evidencing the
existence of intermediate phenotypes in PRS-I deficiency
syndromes and demonstrate that female carriers of PRPS1
mutations can be as severely affected as their male coun-
terparts and therefore, these syndromes may need also to
be considered in females even in the absence of affected
males in the family.
Additional files
Additional file 1: Clinical data of family RP-0482 and primers used
in the study.
Additional file 2: Figure S1. Multifocal ERG and Optical coherence
tomography (OCT) findings suggested a sectorial affectation of perifoveal
photoreceptors. A. Right eye multifocal ERG (mfERG) records in patient
IV:2 demonstrate a reduced function of photoreceptors of perifoveal
region with preserved function of fovea. The ring analysis (see schematic)
goes from the centre to the periphery. Quantitative results of mfERG
analyses are displayed in table format. B. OCT macular cube 512×128
scan show macular thickness in the right eye from patient IV:2. ILM: inner
limiting membrane; RPE: retinal pigment epithelium. Top left: fundus
image with scan cube overlay. Top right: macular thickness significance
map. The central innermost 1-mm-diameter circle represents the central
subfield; inner superior, inner nasal, inner inferior, and inner temporal
areas bounded by the 3-mm-diameter circle form the inner macula; outer
superior, outer nasal, outer inferior, and outer temporal areas bounded by
the 6-mm-diameter circle form the outer macula. Retinal thickness values
from ILM to RPE are compared to the normative data. Middle and bottom
left: cross-sectional OCT scans. Middle right: 3days surface maps: the
ILM-RPE, displaying the retinal thickness in three dimensions. Bottom
right: central subfield thickness, overall average macular thickness, and
overall macular volume compared to normative data are displayed in
table format. Reduction in the retinal thickness in the perifoveal region
with a normal foveal thickness is also evidenced.
Additional file 3: Table S1 and S2. Genetic variants obtained (single
nucleotide variants –SNV-, Table S1, and insertion deletion variants –indels-,
Table S2) after the first variant filtering analysis. Table S3. Variants yielded by
the second filtering of the 141 variants based on the novelty, conservation
across species according to the values from PhyloP and GERP++, predicted
pathogenicity at least by two of the systems evaluated and expression in
the retina. 1KGP: Minor allele frequency in the 1000 Genome Project, ESP:
Minor allele frequency in the NHLBI GO Exome Sequencing Project. For
PhyloP prediction, C: Conserved, NC: Not conserved. For pathogenicity
prediction systems, B: benign, D: deleterious (LRT), or damaging (SIFT) or
disease causing (MutationTaster), N: neutral (LRT) or polymorphism
(MutationTaster), NA: missing data, PrD: probably damaging, PsD: possibly
damaging, T: tolerated, U: Unknown.
Abbreviations
CMTX5: X-linked Charcot-Marie-Tooth, type 5; DFN2: X-linked non-syndromic
sensorineural deafness; Indel: Insertion/deletion polymorphism; OA: Optic
atrophy; PRPP: Phosphoribosyl pyrophosphate; PRS: Phosphoribosyl
pyrophosphate synthetase; RP: Retitinis pigmentosa; SNV: Nonsynonymous
single nucleotide variant; WES: Whole exome sequencing.
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